mtrx1011a

MTRX1011A is a humanized monoclonal antibody that targets the CD4 receptor on both effector and regulatory T cells. It is a modified version of the earlier antibody TRX1 and includes an N434H amino acid substitution to enhance binding to the neonatal Fc receptor (FcRn), which was intended to improve pharmacokinetics by reducing nonspecific elimination. The drug acts as an immunosuppressant by down-modulating CD4 expression without depleting T cells, aiming to block activation and function of pathogenic T effector cells while favoring regulatory T cell dominance. This mechanism was developed for potential treatment of autoimmune diseases such as rheumatoid arthritis. Clinical studies showed dose-dependent pharmacodynamic effects but only modest reduction in disease activity; higher doses were limited by skin toxicity (pruritic papular rash). Development has been discontinued for rheumatoid arthritis[1][3][4][6].

Other names

anti-CD4 monoclonal antibodyanti-CD-4 monoclonal antibodyanti-CD 4 monoclonal antibody